214 related articles for article (PubMed ID: 27696012)
1. Intermittent vs. Continuous Anticoagulation theRapy in patiEnts with Atrial Fibrillation (iCARE-AF): a randomized pilot study.
Stavrakis S; Stoner JA; Kardokus J; Garabelli PJ; Po SS; Lazzara R
J Interv Card Electrophysiol; 2017 Jan; 48(1):51-60. PubMed ID: 27696012
[TBL] [Abstract][Full Text] [Related]
2. Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study.
Waks JW; Passman RS; Matos J; Reynolds M; Thosani A; Mela T; Pederson D; Glotzer TV; Zimetbaum P
Heart Rhythm; 2018 Nov; 15(11):1601-1607. PubMed ID: 29981863
[TBL] [Abstract][Full Text] [Related]
3. Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study.
Passman R; Leong-Sit P; Andrei AC; Huskin A; Tomson TT; Bernstein R; Ellis E; Waks JW; Zimetbaum P
J Cardiovasc Electrophysiol; 2016 Mar; 27(3):264-70. PubMed ID: 26511221
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
6. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
[TBL] [Abstract][Full Text] [Related]
7. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS; Lip GY
Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
[TBL] [Abstract][Full Text] [Related]
8. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding.
Mascarenhas DA; Farooq MU; Ziegler PD; Kantharia BK
Europace; 2016 Jun; 18(6):799-806. PubMed ID: 26614520
[TBL] [Abstract][Full Text] [Related]
9. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
10. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.
Larsen TB; Potpara T; Dagres N; Proclemer A; Sciarrafia E; Blomström-Lundqvist C;
Europace; 2015 May; 17(5):819-24. PubMed ID: 25926476
[TBL] [Abstract][Full Text] [Related]
11. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
12. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
[TBL] [Abstract][Full Text] [Related]
13. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation.
Müller P; Halbfass P; Szöllösi A; Dietrich JW; Fochler F; Nentwich K; Roos M; Krug J; Schmitt R; Mügge A; Deneke T
J Interv Card Electrophysiol; 2016 Sep; 46(3):203-11. PubMed ID: 27020439
[TBL] [Abstract][Full Text] [Related]
14. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
[TBL] [Abstract][Full Text] [Related]
15. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
[TBL] [Abstract][Full Text] [Related]
16. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial.
Brachmann J; Morillo CA; Sanna T; Di Lazzaro V; Diener HC; Bernstein RA; Rymer M; Ziegler PD; Liu S; Passman RS
Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e003333. PubMed ID: 26763225
[TBL] [Abstract][Full Text] [Related]
17. 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry.
Boriani G; Laroche C; Diemberger I; Fantecchi E; Popescu MI; Rasmussen LH; Dan GA; Kalarus Z; Tavazzi L; Maggioni AP; Lip GY
Europace; 2016 May; 18(5):648-57. PubMed ID: 26826133
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.
Martin DT; Bersohn MM; Waldo AL; Wathen MS; Choucair WK; Lip GY; Ip J; Holcomb R; Akar JG; Halperin JL;
Eur Heart J; 2015 Jul; 36(26):1660-8. PubMed ID: 25908774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
